FI962073A - HIV-proteaasin estäjän prodrug-muotoja - Google Patents

HIV-proteaasin estäjän prodrug-muotoja Download PDF

Info

Publication number
FI962073A
FI962073A FI962073A FI962073A FI962073A FI 962073 A FI962073 A FI 962073A FI 962073 A FI962073 A FI 962073A FI 962073 A FI962073 A FI 962073A FI 962073 A FI962073 A FI 962073A
Authority
FI
Finland
Prior art keywords
protease inhibitor
hiv protease
prodrug forms
prodrug
forms
Prior art date
Application number
FI962073A
Other languages
English (en)
Swedish (sv)
Other versions
FI962073A0 (fi
Inventor
Jose Alexander
Dilbir Bindra
Bruce D Dorsey
Arnold J Repta
Joseph P Vacca
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI962073A0 publication Critical patent/FI962073A0/fi
Publication of FI962073A publication Critical patent/FI962073A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI962073A 1993-11-18 1996-05-15 HIV-proteaasin estäjän prodrug-muotoja FI962073A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15420493A 1993-11-18 1993-11-18
PCT/US1994/013085 WO1995014016A1 (en) 1993-11-18 1994-11-14 Prodrugs of an inhibitor of hiv protease

Publications (2)

Publication Number Publication Date
FI962073A0 FI962073A0 (fi) 1996-05-15
FI962073A true FI962073A (fi) 1996-05-15

Family

ID=22550424

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962073A FI962073A (fi) 1993-11-18 1996-05-15 HIV-proteaasin estäjän prodrug-muotoja

Country Status (17)

Country Link
US (1) US5733907A (fi)
EP (1) EP0729467A1 (fi)
JP (1) JPH09505303A (fi)
KR (1) KR960705809A (fi)
CN (1) CN1139432A (fi)
AU (1) AU687128B2 (fi)
CA (1) CA2174649A1 (fi)
CZ (1) CZ140696A3 (fi)
FI (1) FI962073A (fi)
HU (1) HUT76270A (fi)
IL (1) IL111584A0 (fi)
NO (1) NO962000L (fi)
NZ (1) NZ276622A (fi)
PL (1) PL314486A1 (fi)
SK (1) SK61496A3 (fi)
WO (1) WO1995014016A1 (fi)
ZA (1) ZA949127B (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU2012199A (en) * 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
FR2773994B1 (fr) * 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
DK1086076T3 (da) 1998-06-19 2005-03-29 Vertex Pharma Sulfonamidinhibitorer af aspartylprotease
US6319946B1 (en) 1999-02-12 2001-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
AU3275301A (en) * 2000-01-28 2001-08-07 Rohm And Haas Company Enhanced propertied pharmaceuticals
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7202092B2 (en) * 2001-07-13 2007-04-10 Roche Diagnostics Operations, Inc. Indinavir derivatives useful in immunoassay
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2005017106A2 (en) * 2003-06-17 2005-02-24 California Institute Of Technology Libraries of optimized cytochrome p450 enzymes and the optimized p450 enzymes
US7662987B2 (en) * 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
US7109239B2 (en) 2003-08-20 2006-09-19 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US7227028B2 (en) * 2003-12-30 2007-06-05 Xenoport, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541168A (en) * 1895-06-18 Frank e
GB1338169A (en) * 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4661473A (en) * 1984-03-27 1987-04-28 Merck & Co., Inc. Renin inhibitors containing peptide isosteres
EP0395664A1 (en) * 1987-10-21 1990-11-07 The Upjohn Company Renin inhibitors containing a (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety
DK24089D0 (da) * 1989-01-20 1989-01-20 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
US5218114A (en) * 1991-04-10 1993-06-08 Merck & Co., Inc. Cholecystokinin antagonists
US5169952A (en) * 1991-07-02 1992-12-08 Merck & Co., Inc. Stereoselective production of hydroxyamide compounds from chiral α-amino epoxides
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
DK0541168T3 (da) * 1991-11-08 1998-05-11 Merck & Co Inc HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
PL179039B1 (pl) * 1993-07-16 2000-07-31 Merck & Co Inc Sposoby wytwarzania zwiazków posrednich dla inhibitorów proteazy HIV oraz nowy zwiazek posredni PL PL PL
US5463067A (en) * 1993-07-16 1995-10-31 Merck & Co., Inc. Process for making HIV protease inhibitors
AU7973994A (en) * 1993-10-13 1995-05-04 Merck & Co., Inc. Combination therapy for hiv infection
US5455351A (en) * 1993-12-13 1995-10-03 Abbott Laboratories Retroviral protease inhibiting piperazine compounds

Also Published As

Publication number Publication date
ZA949127B (en) 1996-05-17
NO962000D0 (no) 1996-05-15
IL111584A0 (en) 1995-01-24
EP0729467A1 (en) 1996-09-04
AU687128B2 (en) 1998-02-19
FI962073A0 (fi) 1996-05-15
PL314486A1 (en) 1996-09-16
KR960705809A (ko) 1996-11-08
CZ140696A3 (en) 1996-12-11
NZ276622A (en) 1997-09-22
NO962000L (no) 1996-05-15
CN1139432A (zh) 1997-01-01
HUT76270A (en) 1997-07-28
HU9601340D0 (en) 1996-07-29
US5733907A (en) 1998-03-31
SK61496A3 (en) 1996-11-06
CA2174649A1 (en) 1995-05-26
JPH09505303A (ja) 1997-05-27
WO1995014016A1 (en) 1995-05-26
AU1096095A (en) 1995-06-06

Similar Documents

Publication Publication Date Title
DE69434214D1 (de) HIV protease inhibitoren
NO932620D0 (no) Amindiol-proteaseinhibitorer
NO306458B1 (no) DP-IV-serin proteaseinhibitorer
FI951059A0 (fi) HIV-aspartyyliproteaasin sulfonamidi-inhibiittoreita
FI962073A (fi) HIV-proteaasin estäjän prodrug-muotoja
FI943234A (fi) Ihmisen Kunitz-tyyppisen proteaasiestäjän muunnos
PH31249A (en) Inhibitors of hiv protease.
FI935644A (fi) Retrovirusten proteaasi-inhibiittoreita
FI932847A (fi) Hiv-proteasinhibitorer som aer anvaendbara foer behandling av aids
MX9100121A (es) Inhibidores de proteasas asparticas
DE69312093D1 (de) Prodrug von entzündungshemmenden 3-acyl-2-oxindol-1-carboxamiden
NO920023L (no) Hiv-proteaseinhibitorer
NO994415L (no) HIV proteaseinhibitorer
MX9204259A (es) Compuestos inhibidores de proteasa retroviral.
SE9501466D0 (sv) Antiviral protease inhibition
SG49247A1 (en) Hiv protease inhibitors